Thromboxane B2 metabolite methods for optimizing aspirin dosage

Details Thromboxane B2 metabolite methods for optimizing aspirin dosage Thromboxane B2 metabolite methods for optimizing aspirin dosage

2005-11-22

2005-11-22

Gitomer, Ralph (Department: 1651)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving blood clotting factor

C435S069200

Reexamination Certificate

active

06967083

ABSTRACT:
Disclosed are unique methods for identifying the lowest, yet optimal, aspirin doses for patients. These methods are also characterized as having little to no aspirin-related side-effects. These methods may be used pre- as well as post-thrombotic event, and employs a patient's urinary thromboxane B2metabolic levels (e.g., 11-dehydrothromboxane B2), to identify the patient's platelet activation level. A patient's urinary thromboxane B2metabolic level is then used to calculate and appropriate and individualized treatment effective for utilizing platelet activation. Kits for utilizing this technique are also provided. In yet another particular aspect, the invention provides a method for utilizing a random urine sample obtained from a patient to determine whether a patient or particular individual's current dosage of aspirin is providing an adequate and appropriate level of inhibition of platelet activation levels, as compared to inhibition levels observed in individuals not taking aspirin.

REFERENCES:
patent: 2004/0126826 (2004-07-01), Yusuf et al.
Patrignani P. COX-2 is Not Involved in Thromboxane Biosynthesis by Activated Human Platelets. J of Physiology and Pharmacology 50(4)661-7, 1999.
Williams S. Better Increase in Fibrin Gel Porosity by low Dose Than Intermediate Dose Acetylsalicyclic Acid. European Heart J 19(11)1666-1672, 1998.
Perneby C. Optimization of an Enzyme Immunoassay for 11-Dehydrothromboxane B2 in Urine: Comparison with GC-MS. Throbosis Research 96(6)427-436, 1999.
Juul-Moler S., Edvardsson N., Jahnmatz B., et al., Lancet 1992; 340:1421.
ISIS-2 Collaborative Group; ISIS-2, Lancet 1988; 2: 349.
The Dutch TIA Study Group, N. Engl. J. Med. 1991; 325:1261.
Hirsh J., Dalen J.E., Fuster V., Harker L.B., Patrono C., Roth G., Chest 1995; 108 Suppl.: 247s.
International Stroke Trial Collaborative Group, Lancet 1997; 349: 1569.
CAST (Chinese Acute Stroke Trial) Collaborative Group, Lancet 1997; 349: 1641.
The Medical Research Council's General Practice Research Framework, Lancet 1998;351:233.
Hansson L., Zanchatti A., Carruthers S.G., et al., Lancet 1998; 351:1755.
Fitch L.L., Buchwald H., Matts J.P., Am. Heart J. 1995; 129: 656.
Antiplatelet Trialists' Collaboration, BMJ 1994; 308: 81.
Hennekens C.H., Peto R., Hutchinson G.B., et al., N. Engl. J. Med. 1988; 318:923.
Manson J.E., Stampfer MI, Colditz G.A., et al., JAMA 1991; 266: 521.
Ridker P.M., Manson J.E., Buring J.E., Muller J.E., Hennekens C.H., Circulation 1990;82:897.
Buring J.E., Hennekens C.H., J. Myocardial Ischemia 1992; 4: 27.
Roderick P.J., Wilkes H.C., Meade T. W., Br. J. Clin. Pharmacol. 1993; 35: 219.
Petroski D., Lancet 1997; 349: 430.
Peto R., Gray R., Collins R., et al., BMJ 1988; 296: 313.
Kronmal RA., Hart RG., Manolio T.A., Stroke 1998; 29: 887.
He J., Whelton P.K., Vu B., Klag MI, JAMA 1998; 280: 1930.
Patrona C., Coller B., Dalen J., et al., Chest 1998; 114 Suppl:470s.
Halgason C.M., Hoff J.A., Kindos G.T., Barce L.D., Stroke 1993; 24: 1458.
Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H.
Wu K.K., Hoak J.C., Lancet 11;1974: 924.
Trip M.D., Cats V.M., Van Capelle F.J.L., Vreeken J., New Engl. J. Med. 1990, 322: 1549.
Helgason C.M., Bolin K.M., Hoff J.A., et al., Stroke 1994; 25: 2331.
Pappas J.M., Westengard J.C., Bull B.S., Arch. Path. Lab. Med. 1994; 118: 801.
Mueller M.R., Salat A., Stangl P., Thromb. Haemost 1997; 78: 1003.
Grotemeyer KH., Scharafinski H.W., Husstedt I.W., Thrombos. Res. 1993; 71:397.
Komiya T., Kudo M., Urabe T., Mizuno Y., Stroke 1994; 25: 2337.
Israels L.G., Activation of Permeabilized Platelets by Inositol-1, 4,5-Triphosphate Thrombosis Res 40 499-509 1985.
Rifkin R.M., Effect of Dipyridamole and RA 233 on Human Platelet Function in Vitro Thrombosis DH 29 694-701 1973.
Vane J.R., Botting RM., Semin. Arthr. Rheum. 1997; 25 Suppl. 1: 2.
Lawson, JA., Patrono C., Ciabattone G., et al., Anal. Biocem. 1986, 155: 198.
Schror K., Semin. Thrombos. Hemostas. 1997; 23: 349.
Weber A.A., Zimmennann K.C., Meyer-Kirchrath J., Schror K., Lancet 1999;353: 900.
Pedersen A.K, Fitzgerald G.A., New Engi. J Med. 1984; 311: 1206.
Schmidt E.B., Dyerberg J., Drugs 1994; 47: 405.
Weber P., Dendich A., Machlin L.J., Nutr. 1997; 13: 450.
O'neil C.K., Avila J.R., Fetrow C.W., Nursing 1999; 58.
Jannsen P.L.T.M.K., Akkerman J.-W.N., Hoilman P.C.H., Van Staveren W.A., Zwaginga J-J, Katan M.B., Eur. J. Clin. Nutr. 1995; 49: 365.
Beving H., Eksborg S., Malmgren R.S., et al., Thrombos. Res. 1994; 74:39.
Buerke M., Pittroff W., Meyer J., Darius H., Am. Heart J. 1995; 130:465.
May J.A., Heptinstall S., Cole A.T., Hawkey C.J., Thrombos. Res. 1997; 88: 183.
Samuelsson B., Granstrom E., Green K., et al., Ann. Rev. Biochem. 1975:44:669.
Catella F., Fitzgerald G.A., Thrombos. Res. 1987; 47:647.
Catella F., Healy D., Lawson J.A., et al., Proc. Natl. Acad. Sci. USA 1986; 83: 5861.
Van Kooten F., Ciabattoni G., Koudstaal P.J., Dippel W.J., Patrono C., Stroke 1999;30:546.
Lellouche F., Fradin A., Fitzgerald G., et al., Prostaglandins 1990; 40: 297.

Affiliated with

Also associated with

Rating

Thromboxane B2 metabolite methods for optimizing aspirin dosage does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thromboxane B2 metabolite methods for optimizing aspirin dosage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thromboxane B2 metabolite methods for optimizing aspirin dosage will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3521542